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Abstract
Background: Prostate cancer can be treated with several different modalities, including radiation treatment. Various
prognostic tools have been developed to aid decision making by providing estimates of the probability of different
outcomes. Such tools have been demonstrated to have better prognostic accuracy than clinical judgment alone.
Methods: A systematic review was undertaken to identify papers relating to the prediction of clinical outcomes
(biochemical failure, metastasis, survival) in patients with prostate cancer who received radiation treatment, with the
particular aim of identifying whether published tools are adequately developed, validated, and provide accurate
predictions. PubMed and EMBASE were searched from July 2007. Title and abstract screening, full text review, and
critical appraisal were conducted by two reviewers. A review protocol was published in advance of commencing
literature searches.
Results: The search strategy resulted in 165 potential articles, of which 72 were selected for full text review and
47 ultimately included. These papers described 66 models which were newly developed and 31 which were external
validations of already published predictive tools. The included studies represented a total of 60,457 patients, recruited
between 1984 and 2009. Sixty five percent of models were not externally validated, 57% did not report accuracy and
31% included variables which are not readily accessible in existing datasets. Most models (72, 74%) related to external
beam radiation therapy with the remainder relating to brachytherapy (alone or in combination with external beam
radiation therapy).
Conclusions: A large number of prognostic models (97) have been described in the recent literature, representing
a rapid increase since previous reviews (17 papers, 1966–2007). Most models described were not validated and a
third utilised variables which are not readily accessible in existing data collections. Where validation had occurred,
it was often limited to data taken from single institutes in the US. While validated and accurate models are available
to predict prostate cancer specific mortality following external beam radiation therapy, there is a scarcity of such tools
relating to brachytherapy. This review provides an accessible catalogue of predictive tools for current use and which
should be prioritised for future validation.
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Prostate cancer is the most prevalent cancer in men glo-
bally, with 1.4 million new cases reported in 2013 [1].
Prostate cancer cases increased by 217% between 1990
and 2013 as a result of population growth and aging and
increased uptake of opportunistic screening, particularly
in developing countries [1]. Prostate cancer remains the
leading cause of death among males in 24 of 188 coun-
tries covered by the Global Burden of Disease Cancer
Collaboration [1].
Prostate cancer treatments are varied and include: de-
ferred treatment (active surveillance), watchful waiting,
radical prostatectomy, radiation therapy (with or without
androgen deprivation therapy) or androgen deprivation
therapy (ADT) [2, 3]. Each treatment will achieve differ-
ent outcomes in terms of oncology (e.g., survival or time
to biochemical recurrence), adverse events and patient
reported outcomes such as urinary incontinence and im-
potence. These outcomes are important considerations
when selecting a treatment for prostate cancer patients
and are considered in the context of patient age, life ex-
pectancy, co-morbidities, tumour size, grade and stage
and other risk indicators that influence outcomes and
treatment choice. Determining which treatment choice
is optimal for each patient remains an important chal-
lenge, particularly where directly relevant randomised
controlled data is lacking.
To aid this decision making process, a number of tools
have been developed with nomograms and risk stratifi-
cation systems most commonly used [4]. Nomograms
are graphic tools developed to aid clinical decision mak-
ing and are well established in clinical practice for
prostate cancer, particularly for assisting selection of
treatment approaches based on risk stratification. Such
tools have been shown to improve prediction of out-
comes when compared with clinician judgement alone
[5, 6]. Unfortunately most nomograms currently in use
are likely to be based on dated treatment modalities.
Furthermore predictions based on observations made in
one setting may not be accurate in another (e.g., where
ethnicity or health services differ). Extrapolation of pub-
lished international results to local practice is a known
pitfall that has potential to mislead both clinicians and
patients [7]. These limitations are particularly relevant to
predictive tools designed for use in patients treated with
radiation therapy as this modality has changed signifi-
cantly over the past decade.
Objectives
We aim to identify papers predicting clinical outcomes
for patients with prostate cancer who have been treated
with radiation therapy. We particularly set out to assess
if the tools identified were adequately developed, vali-
dated and provide accurate predictions.
Methods
Protocol and registration
A systematic literature review protocol was developed
for this study and registered before searches commenced
with PROSPERO, an international prospective register of




Papers were eligible for inclusion where they met the
following criteria; Population: Patients with prostate
cancer. Exposure: Treatment with radiation therapy
(including external beam radiation therapy and/or
brachytherapy). Outcome: The generation or validation
of a tool for the prediction of clinical outcomes (bio-
chemical failure [BF], progression to metastases, prostate
cancer specific survival, overall survival). Papers had to
be written in English and published post July 2007. This
date was chosen as it is the search date up to which a
previous systematic review of prognostic tools for
prostate cancer treated by any therapy was undertaken
[4]. Studies were included which described tools using
variables which are currently available in a clinical
setting. This excluded papers including genetic or
molecular variables.
Information sources
Searches were conducted of the Medline database
(PubMed interface) and the EMBASE database.
Search
Disease-specific search terms included: prostate cancer,
prostatic neoplasms, cancer of the prostate, adenocarcin-
oma of the prostate, prostatic cancer, prostate gland
cancer and prostate tumour. Treatment specific search
terms included: radiation therapy, radiotherapy, external
beam radiotherapy, EBRT, brachytherapy, high dose
radiotherapy, low dose radiotherapy and targeted
radiotherapies. Outcome-specific search terms included:
overall survival, progression-free survival, PFS, mortality,
event free survival, EFS, disease free survival, prostate
cancer specific survival, progression to metastases, time
to progression, TTP, biochemical recurrence, BCR,
biochemical failure, neoplasm recurrence. Search terms
used to identify predictive models included: predictive
tools, nomograms, risk stratification, Partin tables, regres-
sion tree analysis, Artificial Neural Networks, CAPRA-S
or CAPRA score, risk estimates, algorithms, predictive
accuracy, diagnostic test accuracy, Kattan tables/
nomograms.
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Study selection
Study selection included three phases. The titles and ab-
stracts of all studies identified by the search strategy
were compared to the inclusion criteria detailed above
by two authors working independently (ER and MOC).
All studies that appeared likely to meet the inclusion cri-
teria were progressed to full-text review. All discrepan-
cies, where authors reached different conclusions about
the same papers, were resolved through discussion. The
full-texts of these papers were then retrieved and
assessed against the inclusion criteria, again by two au-
thors (ER, JC or MOC) working independently in order
to minimise the impact of human error. Studies that
were identified as meeting all inclusion criteria were
included in the review, while those which did not were
excluded. Again, where there were differences in the au-
thors’ conclusions consensus on the correct decision was
reached through discussion. Finally, the reference lists of
included papers were screened for any additional rele-
vant papers which may have been missed by the search
strategy. All new titles identified were then reviewed as
described above.
Data collection process and data items
After full text review, data extraction was undertaken by
one reviewer (ER, JC or MOC). Items for extraction in-
cluded: manuscript identifiers (author, contact, country,
setting), study methods, population studied (inclusion
criteria, exclusion criteria, baseline characteristics –
dates of recruitment, age, ethnicity, number of patients,
primary treatment, treatment subtype, adjuvant therap-
ies, neoadjuvant therapies), and predictive model charac-
teristics (type of model, variables included, if internal
validation was reported and the type, external validation,
variable definitions, if variables were readily available,
sample size, number of events, definition of outcome,
model accuracy, sensitivity, specificity, concordance
index and receiver operator curve area under the curve).
For assessment as to whether or not variables were
considered ‘readily available’ the minimum data set used
by the only national prostate cancer registry (Prostate
Cancer Outcomes Registry, Australia and New Zealand
Australian [8]) was used as a guide.
Quality assessment
Quality assessment was performed by two reviewers
(ER, JC or MOC) for each paper. Four questions were
selected for this assessment: 1. Was the defined repre-
sentative sample of patients assembled at a common
(usually early) point in the course of their disease? 2.
Was patient follow-up sufficiently long and complete? 3.
Were outcome criteria either objective or applied in a
‘blind’ fashion? And 4. If subgroups with different prog-
noses were identified, did adjustment for important
prognostic factors take place? These questions were se-
lected from the Centre for Evidence Based Medicine
‘Critical appraisal of prognostic studies’ tool [9]. Discrep-
ancies between reviewers were discussed and consensus
reached. Questions that were answered positively >75%
of the time were considered to present a low risk of bias,
those ≤75 to >50% a moderate risk of bias, and any
≤50% a high risk of bias. Data extraction and quality as-
sessment were performed using the online tool
‘Covidence’.
Results
The search strategy resulted in 165 potentially relevant
abstracts/articles and these were reduced to 72 once du-
plicates were removed and title and abstracts were
screened (Fig. 1). The full-text of these papers was
reviewed against the inclusion criteria (reasons for exclu-
sion are reported in Additional file 1: Table S1a and b)
and 47 finally selected. Study recruitment periods varied
considerably with the earliest patients being from 1984
[10] and the latest 2009 [10–13] (Table 1). The popula-
tions of individual studies varied from 80 [14] to 7,839
[14, 15] with a combined population of 60,457 (Tables 2,
3 and 4). The majority of studies were retrospective
(n = 38), however seven studies recruited prospective
cohorts (for one study [16] it was not stated whether
it was retrospective or prospective).
The 47 papers finally included in this review described
97 individual predictive models. Of these models, 16
related to brachytherapy treatment (Table 2), 72 to ex-
ternal beam radiation therapy (Table 3) and nine to a
combination of brachytherapy and external beam radi-
ation therapy (Table 4).
Across all radiation treatment modalities, outcomes
relating to PSA levels post treatment were most com-
mon (39 models) followed by prostate cancer specific
mortality (29 models). Measures of metastases (17) and
overall survival (14 models) were less common (note
that some papers report more than one outcome and
model). Of those studies reporting development of new
Fig. 1 Flow diagram
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Table 1 Summary of papers describing prognostic tools relating to clinical outcomes following radiation therapy (2007–2015)
Author Recruitment
window
Country Population Outcome Study type Setting
Bittner [27] 1995–2006 USA Prostate cancer patients
treated with brachytherapy





Men previously treated with












1995–2008 USA Men with localized disease
who underwent prostatectomy,
received external-beam
radiation, or received primary
androgen deprivation; and
had at least 6 months of
follow-up recorded.





1989–2004 USA Men with prostate cancer
treated with RT.
BCF Retrospective Single centre
D’Amico [42] 1991–2005 USA Men with high-risk prostate
cancer (locally or advanced)
and 10 year life expectancy
treated with brachytherapy







D’Amico [43] 1988–2004 USA Men who underwent RT for





Canada Men with low or intermediate-risk
prostate cancer treated with
brachytherapy, EBRT within a
phase II or III research protocol,
or ERBT outside of a protocol.
BCF Retrospective Single centre
Denham [44] 1996–2000 Australia &
New Zealand
Men with locally advanced
prostate cancer receiving RT
PCSM Prospective Multi-centre
Engineer [9] 1984–2004 India Patients with a histological




Feng [28] 1998–2008 USA Men with clinically localized





Frank [45] 1996–2006 USA, Canada,
Netherlands.
Men with prostate cancer
treated with brachytherapy
with at least 30 months of
follow-up.
PSA failure. Retrospective Multi -centre
Frank [25] 1998–2006 USA Men with prostate cancer
treated with permament
125 I brachytherapy.
5 year BFFF Retrospective Single centre
Halverson [46] 1998–2008 USA Men with clinically localized
prostate cancer treated with
EBRT with or without adjuvant
ADT
BFFF Retrospective Single centre
Huang [47] 1993–2003 USA, Australia Men with clinical Stage
T1c-T3N0M0 prostate
adenocarcinoma treated with





Kaplan [12] 2000–2009 Israel Patients with prostate cancer
treated with 125 I- brachytherapy.
BFFF Retrospective Single centre
Raymond et al. Radiation Oncology  (2017) 12:56 Page 4 of 20
Table 1 Summary of papers describing prognostic tools relating to clinical outcomes following radiation therapy (2007–2015)
(Continued)
Krishnan [20] 2003–2008 Canada Men with intermediate-risk
prostate cancer with
a minimum follow-up of
3 years.
BCF Retrospective Single centre
Kubicek [48] 1998–2004 USA Men with biopsy proven
T1-T2 prostate adenocarcinoma
treated with EBRT & LDR.
CSS Retrospective Single centre
Marshall [11] 1990–2009 USA Men treated with brachytherapy
for biopsy-proven prostate
adenocarcinoma.
BCF Retrospective Single centre
McKenna [49] 1998–2003 USA Men with biopsy-proved
prostate cancer who had











Potters [16] Not stated USA Prostate cancer patients
treated with brachytherapy.
9-year BFFF Retrospective Multi-centre
Proust-Lima
[51]
Not stated USA Men treated for localized
prostate cancer with EBRT.
BCF Prospective Multi-centre
Qian [52] 1998–2008 USA Men who were treated with
EBRT for clinically localized










Sabolch [53] 1998–2008 USA Men treated for localized




Sanpaolo [21] 2000–2004 Italy Men with T1-T3 NO prostate
cancer.
BCF Retrospective Single centre
Slater [54] 1991–1999 USA Randomly selected prostate
cancer patients treated with
proton and photon beam
therapy.
bNED Retrospective Single centre
Spratt [55] 1997–2008 USA Men with localized prostate




Steigler [56] 1996–2000 Australia &
New Zealand
Men with localised advanced
prostate cancer treated with RT
and experienced BCF prior to





and STI from BCF
Retrospective Multi-centre
Sylvester [57] 1988–1992 USA Men with clinically localized






Taylor [58] Not stated USA Men with localized prostate
cancer,NO/MO treated with RT.
Clinical recurrence
(local, regional or distant)
Retrospective Multi-centre
Thames [59] 1987–1995 USA Men with clinical stages T1b,





1998–2008 USA Men with localized prostate
cancer treated with EBRT,
+/− ADT
FFM, PCSM. Prospective Single centre
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models (66), only nine reported validation either intern-
ally or in an additional cohort. Only 67/97 (69%) models
included variables which were considered to be readily
available in existing data sets.
Critical appraisal considered the criteria set by the
CEBM appraisal tool for prognostic studies [9]. Risk of
bias ranged from moderate (Q1; Was the defined repre-
sentative sample of patients assembled at a common
point in the course of their disease? (72%), Q2; Was
patient follow-up sufficiently long and complete? (64%))
to low (Q3; Were outcome criteria either objective or
applied in a ‘blind’ fashion? (85%), Q4; If subgroups with
different prognoses are identified, did adjustment for im-
portant prognostic factors take place? (91%)) (Table 5).
Brachytherapy
In regards to models predicting outcomes following
brachytherapy, Potters et al. [17] report the highest c-
index in a model developed and internally validated
using a cohort of 5,931 patients. This model predicts
9 year freedom from biochemical failure and remains to
be validated externally. Eleven models relating to
Table 1 Summary of papers describing prognostic tools relating to clinical outcomes following radiation therapy (2007–2015)
(Continued)
Vance [60] 1998–2008 USA Men with clinically localized
prostate cancer treated with
EBRT, with or without neoadjuvant
or adjuvant ADT.
BFFF, DMFS, PCSM & OS. Retrospective Single centre





1998–2007 USA Prostate cancer patients who
underwent endorectal






Williams [17] 1991–2002 US, Canada,
Australia










Yu [63] 1987–2001 USA Men with prostate cancer treated
with EBRT.
BCF Retrospective Single centre
Yu [64] 1993–2002 USA Men newly diagnosed with
clinically node-negative, localized
adenocarcinoma of the prostate
treated with EBRT.
BCF Retrospective Single centre
Zaorsky [65] 1992–2004 USA Men with clinical stage T1-4,
NO/NX-N1, MO adenocarcinoma
of the prostate received RT with
or without adjuvant ADT.
BCF,DM, OS. Retrospective Single centre
Zelefsky [66] 1988–2004 USA Men with clinically staged T1-T3
node-negative prostate cancer
treated with 3D-CRT or IMRT.
DMFS, BFFF. Retrospective Single centre
Zelefsky [67] 1998–2000 USA Men with clinically localized
prostate cancer treated with
3D-CRT or IMRT.
DM,PCSM,BFFF Retrospective Single centre
Zelefsky [68] 1988–2004 USA Men with Stage T1-T3 prostate
cancer treated with 3D-CRT
or IMRT.
PSA relapse Retrospective Single centre
Zelefsky [10] 1998–2009 USA Men with clinically localised
prostate cancer treated with
brachytherapy.
BFFF Retrospective Single centre
Zumsteg [69] 1992–2007 USA Men with intermediate-risk prostate
cancer, but without high-risk
features treated with EBRT.
BCF, BFFF, LF,PCSM, DM. Retrospective Single centre
Abbreviations: OS overall survival, CaPSURE Cancer of the Prostate Strategic Urologic Research Endeavour, RT radiotherapy, BCF bio chemical failure, BFFF bio
chemical freedom from failure, PCSM prostate cancer specific mortality, PSA-RFS prostate-specific antigen recurrence-free survival, LF local failure, DM distant
metastases, DMFS distant metastases-free survival, FFM freedom from metastases, HDR-ISBT high-dose-rate interstitial brachytherapy, TTBF time to bio chemical
failure, STI secondary therapeutic intervention, bNED bio chemical no evidence of diseaese, 2D-CRT 2D - Conformal radiotherapy, 3D-CRT 3D -Conformal
radiotherapy, EBRT external beam radiotherapy, LDR brachytherapy low dose rate brachytherapy, NO/NX no nodal involvement, I-125 Iodine 125 brachytherapy
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brachytherapy (69%) did not report model accuracy and
among those models which did report accuracy, all re-
lated to biochemical failure endpoints. Three studies re-
port to be external validations of the Prostogram
nomogram (also known as the Kattan nomogram), all of
which have low c-indices (0.49, 0.51 and 0.66) suggesting
that this model is of limited clinical utility. A c-index of
1 ‘indicates a perfect ability to rank the outcomes in the
order they actually occurred (100% sensitivity and speci-
ficity), whereas 0.5 is a purely random ranking and is
analogous to the area under the receiver operator char-
acteristic curve’ (definition from [18]).
The majority of papers identified in this review re-
ported models relating to external beam radiation ther-
apy (72/97 = 74%). Fifty-four percent (39 of 72) of these
models did not have their accuracy reported. 61% of
models did not report validation (either internal or ex-
ternal, including external validation of already published
models).
External beam radiation therapy
The model relating to external beam radiation therapy
with the highest accuracy was described by Vainshtein
[19], which was an external validation of the CAPRA
stratification in the context of external beam radiation
therapy. The cohort included 374 patients and the
endpoint of prostate cancer specific mortality was pre-
dicted with c-index of 0.86. Accuracy of this model is
also reported for the outcome of biochemical failure and
subgroups of patients receiving long term ADT or short
term ADT, all which had lower accuracy.
External beam radiation therapy with brachy therapy
Nine models were identified which were specific to
patients treated with external beam radiation therapy in
combination with brachytherapy. Of these models, five
(56%) did not report accuracy. The highest accuracy was
reported by Delouya [15, 20] (c-index 0.69) predicting
biochemical failure free survival at 2-years. This study
was based on a cohort of 744 patients and was an exter-
nal validation of the CAPRA score. Prediction at 5-years
was achieved with c-index 0.62.
Table 5 Risk of bias assessment summary table
Study Id Q1 Q2 Q3 Q4
Cooperberg [39] high low low low
Bittner [27] high low high low
Buyyounouski [38] low low low low
Cooperberg (41) low high low low
Delouya [19] low high low low
Engineer [9] low high low low
Feng [28] low low low low
Frank [25] unclear high low low
Frank [45] unclear low unclear low
Halverson [46] low low low low
Huang [47] low low low low
Kaplan [12] unclear high low low
Krishnan [20] low high low low
Kubicek [48] low low low high
Marshall [11] unclear low low low
Potters [16] unclear high low low
Rodrigues [14] high unclear low low
Proust-Lima [51] low low unclear low
Sabolch [53] low low low low
Sanpaolo [21] low low low low
Slater [54] high low low low
Spratt [55] low low low low
Steigler [56] low low low unclear
Taylor [58] low low unclear low
Vainshtein [18] low low low low
Vance [60] low low low low
Wattson [61] low high low low
Westphalen [62] unclear high low low
Williams [17] low high low low
Yoshida [15] unclear low unclear low
Zaorsky [65] low low low low
Zelefsky [10] low high low low
Zelefsky [68] low low low low
Zelefsky [66] low low low low
Zumsteg [69] low low low low
D’Amico [43] low high low low
Yu [64] low low low low
D’Ambrosio [41] unclear low low low
Denham [44] low unclear low low
McKenna [49] unclear high low high
Yu [63] low unclear unclear low
D’Amico [42] low low low low
Zelefsky [67] low low low low
Thames [59] low low unclear low
Table 5 Risk of bias assessment summary table (Continued)
Qian [52] low low low low
Sylvester [57] low low low high
Murgic [50] low high low low
Low/47 34 (72%) 30 (64%) 40 (85%) 43 (91%)
Q1: Was the defined representative sample of patients assembled at a
common (usually early) point in the course of their disease)? Q2: Was patient
follow-up sufficiently long and complete? Q3: Were outcome criteria either
objective or applied in a ‘blind’ fashion? Q4: If subgroups with different prognoses
are identified, did adjustment for important prognostic factors take place?
High = high risk of bias, low = low risk of bias, unclear = unclear if study design
is at high or low risk of bias
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Discussion
Since the publication of previous reviews, there has been
considerable progress in the field of outcomes prediction
following prostate cancer treatment. This review identi-
fied 47 papers published between 2007 and 2015, which
describe 97 predictive tools for men receiving radiother-
apy. This includes 66 models which were newly devel-
oped and 31 which were validations of already published
predictive tools. Consistent with previous reports, most
tools (65%) are yet to be validated in a population out-
side the derivation set. Studies were included from 2007
as the modality of radiation therapy has changed signifi-
cantly over the past decade, and historic data may not
be a useful basis for prognosis. Apart from modality, the
total dose has also significantly increased however, we
found that only five studies [13, 16, 20–22] did not use
data from men treated as far back as the 1990s.
The volume of research carried out in the field of
prognostics has exploded over the last decade. A system-
atic review that included all studies published before
July 2007 (the cut-off date for inclusion in the present
review) identified 17 studies on prognostic models that
related to prostate cancer patients treated with radio-
therapy [4]. In this review 39 new studies were identified
which investigated prognostic markers for BCF. Unfortu-
nately, the majority of new studies did not undertake
validation, mirroring the finding of the previous sys-
tematic review. As validation – particularly external
validation – is vital for the appropriate clinical imple-
mentation of prognostic models, this suggests that re-
sources and efforts are not being efficiently targeted
to improve tools available for clinical practice.
With regards to the methodological quality of the lit-
erature, our critical appraisal found that overall studies
were at low to moderate risk of bias. The greatest risk
was created by insufficient follow-up (defined as a mean
or median of ≥5 years) which only occurred in 64% of
studies. There was also a moderate risk of bias created
by the possibility of included patients being at different
points in the course of their prostate cancer, however in
the majority of cases this was due to insufficient specifi-
city in the description of inclusion criteria as opposed to
reported differences. There was little risk of bias created
by the measurement of outcomes, as the main outcomes
(biochemical failure [various definitions], metastasis, sur-
vival) were objective, or by a lack of adjustment for im-
portant prognostic factors as the essential factors of
prostate cancer prognosis (PSA, Gleason score, and clin-
ical stage) were used nearly universally.
Model accuracy was not reported in 57% of the models
included. Model accuracy was reported to be highest in
Vainshtein 2014 [23] with a c-index of 0.86 derived for
prediction of prostate cancer specific mortality with the
CAPRA score (originally established in [24]), including
the addition of variables for the presence of Gleason 5
and treatment with ADT (this c-index relates to patients
not receiving ADT). This study acts to externally valid-
ate the CAPRA scoring system (with modifications) in
patients treated with external beam radiation therapy,
though this improvement to the score requires further
validation in other populations. Of the remaining 42
models which reported predictive accuracy, c indices
were typically in the 0.70–0.80 range which would be
considered ‘reasonable’ according to Hosmer and Leme-
show [25]. Notably, those papers which did not report
external validation typically had higher c-indices suggest-
ing that original model developments should be consid-
ered optimistic in their predictive capacity. The lowest
c-index (0.49, 95%CI 0.37 to 0.61) was reported for a
study [26] performing external validation of the Prosto-
gram nomogram (originally established in [27]) suggest-
ing this nomogram may have little predictive value.
The predictive tools identified in this review included
joint-modelling approaches but not neural networks
which have featured in previous reviews. This may re-
flect a change in statistical tools available since publica-
tion of earlier catalogues [4]. Two of the survival models
[28, 29] did not account for competing risks when pre-
dicting prostate cancer specific mortality, a potential
weakness which could easily be addressed.
The majority of papers attempted prediction relating
to biochemical recurrence, prostate cancer specific mor-
tality or overall survival with a smaller subset predicting
metastases. Sixteen of the 97 models identified related to
brachytherapy with 72 for external beam radiation ther-
apy and 9 a combination of the two. This could reflect
more wide-spread use of external beam radiation ther-
apy, and we might anticipate more tools relating to HDR
brachytherapy (with or without EBRT) in the future.
There is a dearth of externally validated nomograms
focusing on brachytherapy and brachytherapy in com-
bination with external beam radiation therapy particu-
larly looking at overall survival and cancer specific
survival outcomes.
This study did not explicitly set out to uncover tools
incorporating novel variables, but only those which
could be used in current clinical settings. Despite this,
31% of studies included reference to variables which
have been less studied to date (e.g. mid-point PSA
levels). While such variables may prove useful, there is
currently limited opportunity to validate these observa-
tions using existing datasets. It is possible that add-
itional variables including standardised measures of
comorbidity, imaging features or genetic markers,
which are becoming more accessible may help to
improve the accuracy of future models. For a recent
review of potential molecular and genetic candidate see
Hall et al. 2016 [30].
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Most predictive tools identified in this review were de-
veloped in US populations. This observation should be
considered by clinicians who are based outside the US
when selecting a predictive model to assist treatment deci-
sion making. Where possible, tools validated in a setting
similar to one’s own clinical practice should be selected for
use. The number of tools available internationally would
be increased with additional validation work conducted
outside the US and particularly in multi-national cohorts.
We observed a large degree of variation in the quality of
reporting clinical predictive tools. This may stem from the
fact that authors are not aware of reporting guidelines in the
field or indeed that such guidelines exist. The TRIPOD
guidelines (http://www.equator-network.org/reporting-guide
lines/tripod-statement/) for reporting of multivariable predic-
tion models were published in March 2015, shortly before
the cut-off for papers included in this review. These guide-
lines have been widely endorsed and published in key
journals [31–39]. Further publication of multivariable models
would benefit greatly from adherence to these guidelines.
Conclusions
Tools which aid decision making offer more accurate pre-
diction of clinical outcomes when compared to clinical
judgement alone. This understanding has led to a large in-
crease in the number of predictive tools relating to clinical
outcomes post radiation therapy between 2007 and 2015.
This review identifies 47 papers describing 97 models
published in the period, a substantial increase compared
to the 17 models previously described between 1966 and
2007. Of the models identified, 65% had no external valid-
ation and 57% did not report accuracy. Thirty one percent
of models included variables which are not part of typical
registry data sets, and are therefore difficult to validate.
Despite these limitations, there are accurate and externally
validated models for external beam radiation therapy
treatment which predict prostate cancer specific mortality.
There are fewer models which accurately predict out-
comes following brachytherapy (alone or in combination
with external beam radiation therapy). This review pro-
vides an accessible catalogue of predictive tools which
could be used currently (i.e. those with high accuracy after
external validation) and identifies those which should be
prioritised for future validation.
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